Phase 2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Recurrent Survivin-Expressing Diffuse Large B-Cell Lymphoma (DLBCL)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs EMD 640744 (Primary) ; Cyclophosphamide
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors Immunovaccine
- 17 Jul 2017 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.
- 17 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated